FASE II ONDERZOEK NAAR DE
EFFECTIVITEIT VAN PAZOPANIB BIJ PATIËNTEN MET BAARMOEDERKANKER.

1. Written informed consent;

2. Age ≥ 18 years;

3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;

4. Histologically or cytologically confirmed diagnosis of endometrial cancer;

5. Metastatic disease or locally advanced tumor not amenable to local therapy;

6. Documented progressive disease before enrolment;

7. Measurable lesions outside irradiated field or progressive measurable lesions in irradiated
area;

8. Not eligible for hormonal therapy (because of negative hormone receptor/poor differentiation,
or after failure of hormonal therapy);

9. Previous failure of chemotherapy, or refusal to undergo chemotherapy or chemo-naive
patients not suitable for chemotherapy;

10. Adequate organ system function.

1. Prior malignancy. Note: Subjects who have had another malignancy and have been disease-free for 5 years, or subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible;

2. History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal
carcinomatosis, except for individuals who have previously-treated CNS metastases, are
asymptomatic, with no radiological signs of progression and have had no requirement for
steroids or anti-seizure medication for 6 months prior to first dose of study drug;

3. Clinically significant gastrointestinal abnormalities that may increase the risk for
gastrointestinal bleeding or may affect absorption of investigational product;

4. Presence of uncontrolled infection;

5. Corrected QT interval (QTc) > 480 msecs using Bazett’s formula;

6. History of major cardiovascular conditions within the past 6 months or poorly controlled
hypertension, history of cerebrovascular accident including transient ischemic attack (TIA),
pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.
Note: Subjects with recent DVT who have been treated with therapeutic anti-coagulating
agents for at least 6 weeks are eligible;

7. Prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence
of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not
considered to be major);

8. Evidence of active bleeding or bleeding diathesis;

9. Treatment with any of the following anti-cancer therapies: radiation therapy, surgery or tumor embolization within 14 days prior to the first dose of pazopanib OR chemotherapy,
immunotherapy, biologic therapy, investigational therapy or hormonal therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of pazopanib.